EMMANUEL SCALAIS | Medicine and Health Sciences | Outstanding Scientist Award

Posted on by sciencefather

Dr.EMMANUELSCALAIS|MedicineandHealth Sciences| Outstanding Scientist Award

MD at NEPE, Luxembourg.

Dr. Emmanuel Scalais is the Chief Physician of the Pediatric Neurology Department at Centre Hospitalier de Luxembourg (CHL)He has authored 82 publications and has been cited 2,877 times in the field of pediatric neurology.His clinical expertise includes conditions such as homocystinuria, vitamin B12 deficiency anemia, and exocrine pancreatic insufficiency.

professional profiles📖

Education 🎓

Secondary School: Humanity Greco-Latine (June 1972), Collège du Sacré-Coeur, Charleroi, BelgiumHigh School: Université Catholique de LouvainBaccalauréat en Philosophie: Magna cum Laude (June 1975)Doctor of Medicine: Laude (June 1979)

work Experience💼

1988-2002: Pediatric Neurologist, CHC Espérance & Saint Vincent, Liège, Belgium (Full-time)Lecturer: Pediatric Neurology Course for nurses at “School of Sainte-Julienne,” LiègeLecturer: “Medical Approach of Handicap” in Orthopédagogie2003-2024: Pediatric Neurologist, Centre Hospitalier de Luxembourg, Department of Pediatrics (Full-time)Head of Pediatric Neurology Division (2014-2018, 2018-2024)Lecturer: Pediatric Neurology Course for nurses at “Lycée Technique pour Professions de Santé” (2006-2024)

Research Focus

Dr. Scalais has authored numerous peer-reviewed articles, with a focus on pediatric neurology, metabolic disorders, and neonatal brain function. Notable contributions include:Research on phenobarbital’s effects on cerebral blood flow in newbornsStudies on very long-chain acyl-CoA dehydrogenase deficiency as a cause of neonatal sudden infant deathInvestigations into early myoclonic epilepsy linked to CoQ10 deficiencyDiagnostic and prognostic value of evoked potentials in neonatal hypoxiaCase studies on mitochondrial disorders, such as Leigh’s encephalopathy and POLG mutationsHydroxocobalamin dose intensification in early-onset cobalamin metabolism defects

Conclusion

Dr. Scalais based on his , , and . While increasing could further strengthen his profile, his current body of work already demonstrates and .is highly suitable for this awardsignificant contributions to pediatric neurology researchclinical impactinternational collaborationshigh-impact publications, principal investigator roles, and research fundingoutstanding scientific meritlong-term dedication to pediatric neurology

📚Publications to Noted

  • Scalais E, Beharry K, Papageorgiou A, Bureau M, Aranda JV (1992). Effects of phenobarbital on cerebral blood flow in the newborn piglet. Developmental Pharmacology and Therapeutics, 19(1), 10-18. [doi: 10.1159/000457457]

  • Scalais E, Bottu J, Wanders RJ, Ferdinandusse S, Waterham HR, De Meirleir L (2015). Familial very long chain acyl-CoA dehydrogenase deficiency as a cause of neonatal sudden infant death: improved survival by prompt diagnosis. American Journal of Medical Genetics Part A, 167A(1), 211-214. [doi: 10.1002/ajmg.a.36803]

  • Scalais E, Chafai R, Van Coster R, Bindl L, Nuttin C, Panagiotaraki C, Seneca S, Lissens W, Ribes A, Geers C, Smet J, De Meirleir L (2013). Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). European Journal of Paediatric Neurology, 17(6), 625-630. [doi: 10.1016/j.ejpn.2013.05.013]

  • Scalais E, Connerotte AC, Despontin K, Biver A, Ceuterick-de Groote C, Alders M, Kolivras A, Hachem JP, De Meirleir L (2016). Shwachman-Diamond syndrome presenting with early ichthyosis, associated dermal and epidermal intracellular lipid droplets, hypoglycemia, and later distinctive clinical SDS phenotype. American Journal of Medical Genetics Part A, 170(7), 1799-1805. [doi: 10.1002/ajmg.a.37673]

  • Scalais E, Francois A, Nuttin C (1996). [Diagnostic and prognostic value of evoked potentials facing cerebral hypoxia in newborn infants]. Archives de Pédiatrie, 3 Suppl 1, 251s-253s. [doi: 10.1016/0929-693x(96)86058-1]

  • Scalais E, Francois B, Schlesser P, Stevens R, Nuttin C, Martin JJ, Van Coster R, Seneca S, Roels F, Van Goethem G, Lofgren A, De Meirleir L (2012). Polymerase gamma deficiency (POLG): clinical course in a child with a two-stage evolution from infantile myocerebrohepatopathy spectrum to an Alpers syndrome and neuropathological findings of Leigh’s encephalopathy. European Journal of Paediatric Neurology, 16(5), 542-548. [doi: 10.1016/j.ejpn.2012.01.013]

  • Scalais E, Francois-Adant A, Nuttin C, Bachy A, Guerit JM (1998). Multimodality evoked potentials as a prognostic tool in term asphyxiated newborns. Electroencephalography and Clinical Neurophysiology, 108(2), 199-207. [doi: 10.1016/s0168-5597(97)00076-2]

  • Scalais E, Geron C, Pierron C, Cardillo S, Schlesser V, Mataigne F, Borde P, Regal L (2023). Would early versus late hydroxocobalamin dose intensification treatment prevent cognitive decline, macular degeneration and ocular disease in 5 patients with early-onset cblC deficiency? Molecular Genetics and Metabolism, 140(3), 107681. [doi: 10.1016/j.ymgme.2023.107681]

  • Scalais E, Nuttin C, Seneca S, Smet J, De Paepe B, Martin JJ, Stevens R, Pierart F, Battisti O, Lissens W, De Meirleir L, Van Coster R (2007). Infantile presentation of the mitochondrial A8344G mutation. European Journal of Neurology, 14(11), e3-5. [doi: 10.1111/j.1468-1331.2007.01926.x]

  • Scalais E, Osterheld E, Geron C, Pierron C, Chafai R, Schlesser V, Borde P, Regal L, Laeremans H, van Gassen KLI, van den Heuvel LPWJ, De Meirleir L (Under revision). Parenteral Hydroxocobalamin Dose Intensification in 5 Patients with Different Types of Early Onset Intracellular Cobalamin Defects: Clinical and Biochemical Responses. Journal of Inherited Metabolic Disease.